

# Muhammad Abdul-Ghani

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/9019106/muhammad-abdul-ghani-publications-by-citations.pdf>

**Version:** 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

191  
papers

44,918  
citations

90  
h-index

202  
g-index

202  
ext. papers

49,192  
ext. citations

8.6  
avg, IF

7.76  
L-index

#	Paper	IF	Citations
191	Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. <i>Diabetes Care</i> , <b>1999</b> , 22, 1462-70	14.6	4139
190	Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. <i>Diabetes Care</i> , <b>1991</b> , 14, 173-94	14.6	3010
189	Glucose clamp technique: a method for quantifying insulin secretion and resistance. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , <b>1979</b> , 237, E214-23	6	2392
188	Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. <i>Diabetes</i> , <b>1988</b> , 37, 667-87	0.9	2174
187	Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. <i>Diabetes</i> , <b>2009</b> , 58, 773-95	0.9	1832
186	Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: Potential role of PGC1 and NRF1. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2003</b> , 100, 8466-71	11.5	1595
185	A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. <i>New England Journal of Medicine</i> , <b>2006</b> , 355, 2297-307	59.2	1311
184	Quantitation of muscle glycogen synthesis in normal subjects and subjects with non-insulin-dependent diabetes by <sup>13</sup> C nuclear magnetic resonance spectroscopy. <i>New England Journal of Medicine</i> , <b>1990</b> , 322, 223-8	59.2	1052
183	Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. <i>New England Journal of Medicine</i> , <b>1995</b> , 333, 541-9	59.2	1049
182	Glucose toxicity. <i>Diabetes Care</i> , <b>1990</b> , 13, 610-30	14.6	817
181	Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle. <i>Journal of Clinical Investigation</i> , <b>2000</b> , 105, 311-20	15.9	812
180	Effects of insulin on peripheral and splanchnic glucose metabolism in noninsulin-dependent (type II) diabetes mellitus. <i>Journal of Clinical Investigation</i> , <b>1985</b> , 76, 149-55	15.9	799
179	Type 2 diabetes mellitus. <i>Nature Reviews Disease Primers</i> , <b>2015</b> , 1, 15019	51.1	651
178	Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. <i>Journal of Clinical Investigation</i> , <b>1987</b> , 79, 1510-5	15.9	606
177	Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus. Evidence for multiple sites of insulin resistance. <i>Journal of Clinical Investigation</i> , <b>1989</b> , 84, 205-13	15.9	585
176	Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009. <i>Diabetologia</i> , <b>2010</b> , 53, 1270-87	10.3	573
175	Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2002</b> , 87, 2784-91	5.6	554

174	Pioglitazone for diabetes prevention in impaired glucose tolerance. <i>New England Journal of Medicine</i> , <b>2011</b> , 364, 1104-15	59.2	537
173	Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. <i>Journal of Clinical Investigation</i> , <b>2014</b> , 124, 509-14	15.9	514
172	Regulation of splanchnic and peripheral glucose uptake by insulin and hyperglycemia in man. <i>Diabetes</i> , <b>1983</b> , 32, 35-45	0.9	499
171	Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2004</b> , 89, 463-78	5.6	492
170	Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. <i>Nutrients</i> , <b>2013</b> , 5, 1544-60	6.7	474
169	Fasting hyperglycemia in non-insulin-dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake. <i>Metabolism: Clinical and Experimental</i> , <b>1989</b> , 38, 387-95	12.7	451
168	beta-Cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2005</b> , 90, 493-500	5.6	407
167	Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects. <i>Gastroenterology</i> , <b>2007</b> , 133, 496-506	13.3	397
166	A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes. <i>Diabetes</i> , <b>2003</b> , 52, 2461-74	0.9	388
165	Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance: results from the Veterans Administration Genetic Epidemiology Study. <i>Diabetes</i> , <b>2006</b> , 55, 1430-5	0.9	384
164	The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. <i>Diabetes, Obesity and Metabolism</i> , <b>2012</b> , 14, 5-14	6.7	342
163	Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. <i>Diabetes Care</i> , <b>2001</b> , 24, 710-9	14.6	335
162	Pathogenesis of insulin resistance in skeletal muscle. <i>Journal of Biomedicine and Biotechnology</i> , <b>2010</b> , 2010, 476279		325
161	Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. <i>Current Medical Research and Opinion</i> , <b>2008</b> , 24, 2943-52	2.5	321
160	The effects of glucose and insulin on renal electrolyte transport. <i>Journal of Clinical Investigation</i> , <b>1976</b> , 58, 83-90	15.9	320
159	Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>1991</b> , 73, 1294-301	5.6	317
158	Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>1996</b> , 81, 4059-67	5.6	306
157	Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2004</b> , 89, 200-6	5.6	305

156	CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2017 EXECUTIVE SUMMARY. <i>Endocrine Practice</i> , <b>2017</b> , 23, 207-238	3.2	302
155	Insulin resistance and endothelial dysfunction: the road map to cardiovascular diseases. <i>Diabetes/Metabolism Research and Reviews</i> , <b>2006</b> , 22, 423-36	7.5	301
154	Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. <i>Endocrine Reviews</i> , <b>2011</b> , 32, 515-31	27.2	292
153	Obesity and insulin resistance in humans: a dose-response study. <i>Metabolism: Clinical and Experimental</i> , <b>1990</b> , 39, 452-9	12.7	290
152	Dose-response effect of elevated plasma free fatty acid on insulin signaling. <i>Diabetes</i> , <b>2005</b> , 54, 1640-8	0.9	288
151	Glucose intolerance and aging. <i>Diabetes Care</i> , <b>1981</b> , 4, 493-501	14.6	284
150	Elevated toll-like receptor 4 expression and signaling in muscle from insulin-resistant subjects. <i>Diabetes</i> , <b>2008</b> , 57, 2595-602	0.9	279
149	Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. <i>Nature Reviews Nephrology</i> , <b>2017</b> , 13, 11-26	14.9	265
148	Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats. <i>Journal of Clinical Investigation</i> , <b>1987</b> , 80, 1037-44	15.9	264
147	Contributions of beta-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. <i>Diabetes Care</i> , <b>2006</b> , 29, 1130-9	14.6	262
146	Beta-cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study. <i>Diabetologia</i> , <b>2004</b> , 47, 31-9	10.3	257
145	Influence of hyperinsulinemia, hyperglycemia, and the route of glucose administration on splanchnic glucose exchange. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1978</b> , 75, 5173-7	11.5	250
144	Effect of sustained physiologic hyperinsulinaemia and hyperglycaemia on insulin secretion and insulin sensitivity in man. <i>Diabetologia</i> , <b>1994</b> , 37, 1025-35	10.3	248
143	The metabolic profile of NIDDM is fully established in glucose-tolerant offspring of two Mexican-American NIDDM parents. <i>Diabetes</i> , <b>1992</b> , 41, 1575-86	0.9	247
142	Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes. <i>Diabetes</i> , <b>2003</b> , 52, 1364-70	0.9	240
141	Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients. <i>Diabetologia</i> , <b>2001</b> , 44, 2210-9	10.3	236
140	Role of lipid oxidation in pathogenesis of insulin resistance of obesity and type II diabetes. <i>Diabetes</i> , <b>1987</b> , 36, 1341-50	0.9	235
139	The disposal of an oral glucose load in patients with non-insulin-dependent diabetes. <i>Metabolism: Clinical and Experimental</i> , <b>1988</b> , 37, 79-85	12.7	235

138	A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. <i>Archives of Internal Medicine</i> , <b>2004</b> , 164, 2097-104		224
137	SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study. <i>Diabetes Care</i> , <b>2016</b> , 39, 717-25	14.6	211
136	Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin. <i>Diabetes Care</i> , <b>2015</b> , 38, 384-93	14.6	210
135	Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidaemia and atherosclerosis. <i>Netherlands Journal of Medicine</i> , <b>1997</b> , 50, 191-7	0.5	199
134	Effect of insulin on the distribution and disposition of glucose in man. <i>Journal of Clinical Investigation</i> , <b>1985</b> , 76, 357-64	15.9	194
133	Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes. <i>Diabetes Care</i> , <b>2013</b> , 36, 3169-76	14.6	193
132	Lipid infusion decreases the expression of nuclear encoded mitochondrial genes and increases the expression of extracellular matrix genes in human skeletal muscle. <i>Journal of Biological Chemistry</i> , <b>2005</b> , 280, 10290-7	5.4	191
131	The Primary Glucose-Lowering Effect of Metformin Resides in the Gut, Not the Circulation: Results From Short-term Pharmacokinetic and 12-Week Dose-Ranging Studies. <i>Diabetes Care</i> , <b>2016</b> , 39, 198-205	14.6	182
130	Preservation of $\beta$ cell function: the key to diabetes prevention. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2011</b> , 96, 2354-66	5.6	182
129	Insulin binding to monocytes and insulin action in human obesity, starvation, and refeeding. <i>Journal of Clinical Investigation</i> , <b>1978</b> , 62, 204-13	15.9	180
128	Bromocriptine: a novel approach to the treatment of type 2 diabetes. <i>Diabetes Care</i> , <b>2000</b> , 23, 1154-61	14.6	176
127	Physical training and insulin sensitivity. <i>Diabetes/metabolism Reviews</i> , <b>1986</b> , 1, 445-81		176
126	Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30-50% of filtered glucose load in humans. <i>Diabetes</i> , <b>2013</b> , 62, 3324-8	0.9	163
125	Relationship of baseline HbA1c and efficacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trials. <i>Diabetic Medicine</i> , <b>2010</b> , 27, 309-17	3.5	158
124	Insulin resistance and coronary artery disease. <i>Diabetologia</i> , <b>1996</b> , 39, 1345-50	10.3	153
123	Role of Adipose Tissue Insulin Resistance in the Natural History of Type 2 Diabetes: Results From the San Antonio Metabolism Study. <i>Diabetes</i> , <b>2017</b> , 66, 815-822	0.9	152
122	Dysfunctional fat cells, lipotoxicity and type 2 diabetes. <i>International Journal of Clinical Practice</i> , <b>2004</b> , 58, 9-21	2.9	148
121	Effect of a sustained reduction in plasma free fatty acid concentration on intramuscular long-chain fatty Acyl-CoAs and insulin action in type 2 diabetic patients. <i>Diabetes</i> , <b>2005</b> , 54, 3148-53	0.9	146

120	Thiazolidinediones improve beta-cell function in type 2 diabetic patients. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , <b>2007</b> , 292, E871-83	6	145
119	Total Body Fat Content and Fat Topography Are Associated Differently With In Vivo Glucose Metabolism in Nonobese and Obese Nondiabetic Women. <i>Diabetes</i> , <b>1992</b> , 41, 1151-1159	0.9	140
118	Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , <b>2008</b> , 294, E846-52	6	132
117	Effect of physical training on insulin action in obesity. <i>Diabetes</i> , <b>1987</b> , 36, 1379-85	0.9	132
116	Indirect calorimetry: methodological and interpretative problems. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , <b>1990</b> , 258, E399-412	6	126
115	Normalization of blood glucose in diabetic rats with phlorizin treatment reverses insulin-resistant glucose transport in adipose cells without restoring glucose transporter gene expression. <i>Journal of Clinical Investigation</i> , <b>1991</b> , 87, 561-70	15.9	126
114	Rosiglitazone improves downstream insulin receptor signaling in type 2 diabetic patients. <i>Diabetes</i> , <b>2003</b> , 52, 1943-50	0.9	116
113	Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT): a randomized trial. <i>Diabetes, Obesity and Metabolism</i> , <b>2015</b> , 17, 268-75	6.7	115
112	The role of fractional glucose extraction in the regulation of splanchnic glucose metabolism in normal and diabetic man. <i>Metabolism: Clinical and Experimental</i> , <b>1980</b> , 29, 28-35	12.7	109
111	Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus. <i>Diabetologia</i> , <b>2007</b> , 50, 1723-31	10.3	107
110	Insulin resistance is associated with impaired nitric oxide synthase activity in skeletal muscle of type 2 diabetic subjects. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2005</b> , 90, 1100-5	5.6	107
109	Dapagliflozin Enhances Fat Oxidation and Ketone Production in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , <b>2016</b> , 39, 2036-2041	14.6	105
108	Pioglitazone stimulates AMP-activated protein kinase signalling and increases the expression of genes involved in adiponectin signalling, mitochondrial function and fat oxidation in human skeletal muscle in vivo: a randomised trial. <i>Diabetologia</i> , <b>2009</b> , 52, 723-32	10.3	105
107	Reduced skeletal muscle inhibitor of kappaB beta content is associated with insulin resistance in subjects with type 2 diabetes: reversal by exercise training. <i>Diabetes</i> , <b>2006</b> , 55, 760-7	0.9	104
106	Increased glutamine:fructose-6-phosphate amidotransferase activity in skeletal muscle of patients with NIDDM. <i>Diabetes</i> , <b>1996</b> , 45, 302-7	0.9	99
105	Dapagliflozin lowers plasma glucose concentration and improves Ecell function. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2015</b> , 100, 1927-32	5.6	97
104	Effects of exenatide plus rosiglitazone on beta-cell function and insulin sensitivity in subjects with type 2 diabetes on metformin. <i>Diabetes Care</i> , <b>2010</b> , 33, 951-7	14.6	90
103	Predominant role of reduced beta-cell sensitivity to glucose over insulin resistance in impaired glucose tolerance. <i>Diabetologia</i> , <b>2003</b> , 46, 1211-9	10.3	89

102	Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor. <i>Diabetes, Obesity and Metabolism</i> , <b>2017</b> , 19, 1353-1362	6.7	88
101	Distinct cell defects in impaired fasting glucose and impaired glucose tolerance. <i>Diabetes</i> , <b>2012</b> , 61, 447-53	0.9	88
100	Skeletal muscle insulin resistance in normoglycemic subjects with a strong family history of type 2 diabetes is associated with decreased insulin-stimulated insulin receptor substrate-1 tyrosine phosphorylation. <i>Diabetes</i> , <b>2001</b> , 50, 2572-8	0.9	86
99	Insulin Resistance and Atherosclerosis: Implications for Insulin-Sensitizing Agents. <i>Endocrine Reviews</i> , <b>2019</b> , 40, 1447-1467	27.2	85
98	Insulin reduces plasma arginase activity in type 2 diabetic patients. <i>Diabetes Care</i> , <b>2008</b> , 31, 134-9	14.6	83
97	Metabolic and molecular basis of insulin resistance. <i>Journal of Nuclear Cardiology</i> , <b>2003</b> , 10, 311-23	2.1	83
96	Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitus. <i>American Journal of Physiology - Renal Physiology</i> , <b>2015</b> , 309, F889-900	4.3	82
95	Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived?. <i>Diabetes Care</i> , <b>2017</b> , 40, 813-820	14.6	78
94	Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2012</b> , 97, 1615-22	5.6	78
93	Pioglitazone slows progression of atherosclerosis in prediabetes independent of changes in cardiovascular risk factors. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2013</b> , 33, 393-9	9.4	78
92	Discordant effects of a chronic physiological increase in plasma FFA on insulin signaling in healthy subjects with or without a family history of type 2 diabetes. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , <b>2004</b> , 287, E537-46	6	75
91	In vivo actions of peroxisome proliferator-activated receptors: glycemic control, insulin sensitivity, and insulin secretion. <i>Diabetes Care</i> , <b>2013</b> , 36 Suppl 2, S162-74	14.6	72
90	Reduction in hematocrit and hemoglobin following pioglitazone treatment is not hemodilutional in Type II diabetes mellitus. <i>Clinical Pharmacology and Therapeutics</i> , <b>2007</b> , 82, 275-81	6.1	71
89	Prevention of diabetes with pioglitazone in ACT NOW: physiologic correlates. <i>Diabetes</i> , <b>2013</b> , 62, 3920-60.9	6.9	68
88	The effect of pioglitazone on the liver: role of adiponectin. <i>Diabetes Care</i> , <b>2006</b> , 29, 2275-81	14.6	67
87	Glucagon dose-response curve for hepatic glucose production and glucose disposal in type 2 diabetic patients and normal individuals. <i>Metabolism: Clinical and Experimental</i> , <b>2002</b> , 51, 1111-9	12.7	67
86	Once-daily delayed-release metformin lowers plasma glucose and enhances fasting and postprandial GLP-1 and PYY: results from two randomised trials. <i>Diabetologia</i> , <b>2016</b> , 59, 1645-54	10.3	67
85	A test of the hypothesis that the rate of fall in glucose concentration triggers counterregulatory hormonal responses in man. <i>Diabetes</i> , <b>1977</b> , 26, 445-52	0.9	66

84	Effects of pioglitazone on intramyocellular fat metabolism in patients with type 2 diabetes mellitus. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2010</b> , 95, 1916-23	5.6	64
83	Pioglitazone: The forgotten, cost-effective cardioprotective drug for type 2 diabetes. <i>Diabetes and Vascular Disease Research</i> , <b>2019</b> , 16, 133-143	3.3	63
82	Effect of acute physiological hyperinsulinemia on gene expression in human skeletal muscle in vivo. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , <b>2008</b> , 294, E910-7	6	63
81	Effect of loss of first-phase insulin secretion on hepatic glucose production and tissue glucose disposal in humans. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , <b>1989</b> , 257, E241-6	6	62
80	Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients. <i>Diabetes, Obesity and Metabolism</i> , <b>2008</b> , 10, 1204-11	6.7	61
79	Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors. <i>Nature Reviews Nephrology</i> , <b>2021</b> , 17, 319-334	14.9	59
78	The relationship between fasting hyperglycemia and insulin secretion in subjects with normal or impaired glucose tolerance. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , <b>2008</b> , 295, E401-6	6	57
77	Sodium-glucose co-transporter (SGLT) and glucose transporter (GLUT) expression in the kidney of type 2 diabetic subjects. <i>Diabetes, Obesity and Metabolism</i> , <b>2017</b> , 19, 1322-1326	6.7	56
76	The relationship between {beta}-cell function and glycated hemoglobin: results from the veterans administration genetic epidemiology study. <i>Diabetes Care</i> , <b>2011</b> , 34, 1006-10	14.6	52
75	Impaired early- but not late-phase insulin secretion in subjects with impaired fasting glucose. <i>Acta Diabetologica</i> , <b>2011</b> , 48, 209-17	3.9	46
74	Determinants of the increase in ketone concentration during SGLT2 inhibition in NGT, IFG and T2DM patients. <i>Diabetes, Obesity and Metabolism</i> , <b>2017</b> , 19, 809-813	6.7	44
73	Petition to replace current OGTT criteria for diagnosing prediabetes with the 1-hour post-load plasma glucose $\geq$ 55 mg/dl (8.6 mmol/L). <i>Diabetes Research and Clinical Practice</i> , <b>2018</b> , 146, 18-33	7.4	44
72	Mechanisms of glucose lowering of dipeptidyl peptidase-4 inhibitor sitagliptin when used alone or with metformin in type 2 diabetes: a double-tracer study. <i>Diabetes Care</i> , <b>2013</b> , 36, 2756-62	14.6	43
71	Effect of exenatide on splanchnic and peripheral glucose metabolism in type 2 diabetic subjects. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2011</b> , 96, 1763-70	5.6	41
70	UDP-N-acetylglucosamine transferase and glutamine: fructose 6-phosphate amidotransferase activities in insulin-sensitive tissues. <i>Diabetologia</i> , <b>1997</b> , 40, 76-81	10.3	41
69	Physiological hyperinsulinemia impairs insulin-stimulated glycogen synthase activity and glycogen synthesis. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , <b>2001</b> , 280, E712-9	6	41
68	Empagliflozin and Kinetics of Renal Glucose Transport in Healthy Individuals and Individuals With Type 2 Diabetes. <i>Diabetes</i> , <b>2017</b> , 66, 1999-2006	0.9	38
67	Endogenous Glucose Production and Hormonal Changes in Response to Canagliflozin and Liraglutide Combination Therapy. <i>Diabetes</i> , <b>2018</b> , 67, 1182-1189	0.9	36



66	Free fatty acids reduce splanchnic and peripheral glucose uptake in patients with type 2 diabetes. <i>Diabetes</i> , <b>2002</b> , 51, 3043-8	0.9	36
65	Chronic physiologic hyperinsulinemia impairs suppression of plasma free fatty acids and increases de novo lipogenesis but does not cause dyslipidemia in conscious normal rats. <i>Metabolism: Clinical and Experimental</i> , <b>1999</b> , 48, 330-7	12.7	36
64	Revitalization of pioglitazone: the optimum agent to be combined with a sodium-glucose co-transporter-2 inhibitor. <i>Diabetes, Obesity and Metabolism</i> , <b>2016</b> , 18, 454-62	6.7	34
63	Pioglitazone Improves Left Ventricular Diastolic Function in Subjects With Diabetes. <i>Diabetes Care</i> , <b>2017</b> , 40, 1530-1536	14.6	34
62	Empagliflozin Treatment Is Associated With Improved $\beta$ Cell Function in Type 2 Diabetes Mellitus. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2018</b> , 103, 1402-1407	5.6	33
61	Is It Time to Change the Type 2 Diabetes Treatment Paradigm? Yes! GLP-1 RAs Should Replace Metformin in the Type 2 Diabetes Algorithm. <i>Diabetes Care</i> , <b>2017</b> , 40, 1121-1127	14.6	32
60	Reciprocal variations in insulin-stimulated glucose uptake and pancreatic insulin secretion in women with normal glucose tolerance. <i>Journal of the Society for Gynecologic Investigation</i> , <b>1995</b> , 2, 708-15		31
59	Decreased non-insulin-dependent glucose clearance contributes to the rise in fasting plasma glucose in the nondiabetic range. <i>Diabetes Care</i> , <b>2008</b> , 31, 311-5	14.6	29
58	Reciprocal Variations in Insulin-Stimulated Glucose Uptake and Pancreatic Insulin Secretion in Women With Normal Glucose Tolerance. <i>Journal of the Society for Gynecologic Investigation</i> , <b>1995</b> , 2, 708-715		27
57	Combination Therapy With Exenatide Plus Pioglitazone Versus Basal/Bolus Insulin in Patients With Poorly Controlled Type 2 Diabetes on Sulfonylurea Plus Metformin: The Qatar Study. <i>Diabetes Care</i> , <b>2017</b> , 40, 325-331	14.6	26
56	Prediabetes and risk of diabetes and associated complications: impaired fasting glucose versus impaired glucose tolerance: does it matter?. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , <b>2016</b> , 19, 394-399	3.8	26
55	The disposition index does not reflect $\beta$ cell function in IGT subjects treated with pioglitazone. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2014</b> , 99, 3774-81	5.6	25
54	Insulin Resistance the Link between T2DM and CVD: Basic Mechanisms and Clinical Implications. <i>Current Vascular Pharmacology</i> , <b>2019</b> , 17, 153-163	3.3	22
53	What are the pharmacotherapy options for treating prediabetes?. <i>Expert Opinion on Pharmacotherapy</i> , <b>2014</b> , 15, 2003-18	4	20
52	Pleiotropic effects of thiazolidinediones: implications for the treatment of patients with type 2 diabetes mellitus. <i>Hospital Practice (1995)</i> , <b>2013</b> , 41, 132-47	2.2	20
51	Combination Therapy With Canagliflozin Plus Liraglutide Exerts Additive Effect on Weight Loss, but Not on HbA <sub>1c</sub> , in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , <b>2020</b> , 43, 1234-1241	14.6	18
50	Effect of Chronic Hyperglycemia on Glucose Metabolism in Subjects With Normal Glucose Tolerance. <i>Diabetes</i> , <b>2018</b> , 67, 2507-2517	0.9	18
49	Adaptation of Insulin Clearance to Metabolic Demand Is a Key Determinant of Glucose Tolerance. <i>Diabetes</i> , <b>2021</b> , 70, 377-385	0.9	17

48	Pioglitazone inhibits mitochondrial pyruvate metabolism and glucose production in hepatocytes. <i>FEBS Journal</i> , <b>2017</b> , 284, 451-465	5.7	15
47	Insulin secretion, insulin resistance, and obesity <b>1982</b> , 6 Suppl 1, 73-82		14
46	Inhibition of Renal Sodium-Glucose Cotransport With Empagliflozin Lowers Fasting Plasma Glucose and Improves $\beta$ Cell Function in Subjects With Impaired Fasting Glucose. <i>Diabetes</i> , <b>2017</b> , 66, 2495-2502	0.9	12
45	Comprehensive assessment of postischemic vascular reactivity in Hispanic children and adults with and without diabetes mellitus. <i>Pediatric Diabetes</i> , <b>2006</b> , 7, 329-35	3.6	12
44	Mild Physiologic Hyperglycemia Induces Hepatic Insulin Resistance in Healthy Normal Glucose-Tolerant Participants. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2019</b> , 104, 2842-2850	5.6	11
43	Evidence Against an Important Role of Plasma Insulin and Glucagon Concentrations in the Increase in EGP Caused by SGLT2 Inhibitors. <i>Diabetes</i> , <b>2020</b> , 69, 681-688	0.9	11
42	Reduced skeletal muscle phosphocreatine concentration in type 2 diabetic patients: a quantitative image-based phosphorus-31 MR spectroscopy study. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , <b>2018</b> , 315, E229-E239	6	10
41	Discordance Between Central (Brain) and Pancreatic Action of Exenatide in Lean and Obese Subjects. <i>Diabetes Care</i> , <b>2016</b> , 39, 1804-10	14.6	10
40	Differential effect of hyperglycemia and hyperinsulinemia on pathways of hepatic glycogen repletion. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , <b>1991</b> , 260, E731-5	6	9
39	Accuracy of 1-Hour Plasma Glucose During the Oral Glucose Tolerance Test in Diagnosis of Type 2 Diabetes in Adults: A Meta-analysis. <i>Diabetes Care</i> , <b>2021</b> , 44, 1062-1069	14.6	9
38	Efficacy of Exenatide Plus Pioglitazone Vs Basal/Bolus Insulin in T2DM Patients With Very High HbA1c. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2017</b> , 102, 2162-2170	5.6	8
37	Diverted sleeve gastrectomy with ileal transposition in overweight, obese, and morbidly obese patients with type 2 diabetes: results of 1-year follow-up. <i>Surgery for Obesity and Related Diseases</i> , <b>2016</b> , 12, 541-549	3	7
36	The tumor suppressor TMEM127 regulates insulin sensitivity in a tissue-specific manner. <i>Nature Communications</i> , <b>2019</b> , 10, 4720	17.4	7
35	Strong association between insulin-mediated glucose uptake and the 2-hour, not the fasting plasma glucose concentration, in the normal glucose tolerance range. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2014</b> , 99, 3444-9	5.6	7
34	Increase in endogenous glucose production with SGLT2 inhibition is attenuated in individuals who underwent kidney transplantation and bilateral native nephrectomy. <i>Diabetologia</i> , <b>2020</b> , 63, 2423-2433	10.3	7
33	Therapeutic Manipulation of Myocardial Metabolism: JACC State-of-the-Art Review. <i>Journal of the American College of Cardiology</i> , <b>2021</b> , 77, 2022-2039	15.1	7
32	Glucose-Mediated Glucose Disposal at Baseline Insulin Is Impaired in IFG. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2019</b> , 104, 163-171	5.6	7
31	Durability of Triple Combination Therapy Versus Stepwise Addition Therapy in Patients With New-Onset T2DM: 3-Year Follow-up of EDICT. <i>Diabetes Care</i> , <b>2021</b> , 44, 433-439	14.6	7

30	Pioglitazone corrects dysregulation of skeletal muscle mitochondrial proteins involved in ATP synthesis in type 2 diabetes. <i>Metabolism: Clinical and Experimental</i> , <b>2021</b> , 114, 154416	12.7	6
29	Insulin secretion predicts the response to therapy with exenatide plus pioglitazone, but not to basal/bolus insulin in poorly controlled T2DM patients: Results from the Qatar study. <i>Diabetes, Obesity and Metabolism</i> , <b>2018</b> , 20, 1075-1079	6.7	6
28	Slope of change in HbA from baseline with empagliflozin compared with sitagliptin or glimepiride in patients with type 2 diabetes. <i>Endocrinology, Diabetes and Metabolism</i> , <b>2018</b> , 1, e00016	2.7	5
27	Effect of vildagliptin add-on treatment to metformin on plasma asymmetric dimethylarginine in type 2 diabetes mellitus patients. <i>Drug Design, Development and Therapy</i> , <b>2014</b> , 8, 239-43	4.4	5
26	Insulin resistance, hypertension and cellular ion transport systems. <i>Acta Diabetologica</i> , <b>1992</b> , 29, 196-200	3.9	5
25	Glucose lowering and vascular protective effects of cycloset added to GLP-1 receptor agonists in patients with type 2 diabetes. <i>Endocrinology, Diabetes and Metabolism</i> , <b>2018</b> , 1, e00034	2.7	5
24	Glycated hemoglobin versus oral glucose tolerance test in the identification of subjects with prediabetes in Qatari population. <i>BMC Endocrine Disorders</i> , <b>2019</b> , 19, 87	3.3	4
23	Effect of sustained physiologic hyperinsulinaemia and hyperglycaemia on insulin secretion and insulin sensitivity in man <b>1994</b> , 37, 1025		4
22	Effect of Mild Physiologic Hyperglycemia on Insulin Secretion, Insulin Clearance, and Insulin Sensitivity in Healthy Glucose-Tolerant Subjects. <i>Diabetes</i> , <b>2021</b> , 70, 204-213	0.9	4
21	Impaired Suppression of Glucagon in Obese Subjects Parallels Decline in Insulin Sensitivity and Beta-Cell Function. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2021</b> , 106, 1398-1409	5.6	4
20	Impact of ethnicity and obesity on insulin resistance in two ethnic groups at very high risk of type 2 diabetes. <i>Diabetes and Metabolism</i> , <b>2017</b> , 43, 292-294	5.4	3
19	Fiber orientation measurements by diffusion tensor imaging improve hydrogen-1 magnetic resonance spectroscopy of intramyocellular lipids in human leg muscles. <i>Journal of Medical Imaging</i> , <b>2015</b> , 2, 026002	2.6	3
18	Impaired left ventricular diastolic function in T2DM patients is closely related to glycemic control. <i>Endocrinology, Diabetes and Metabolism</i> , <b>2018</b> , 1, e00014	2.7	3
17	Hormone-substrate changes with exenatide plus dapagliflozin versus each drug alone: The randomized, active-controlled DURATION-8 study. <i>Diabetes, Obesity and Metabolism</i> , <b>2020</b> , 22, 99-106	6.7	3
16	Adiponectin Alleviates Diet-Induced Inflammation in the Liver by Suppressing MCP-1 Expression and Macrophage Infiltration. <i>Diabetes</i> , <b>2021</b> , 70, 1303-1316	0.9	3
15	Insulin Resistance and Hyperinsulinemia: the Egg and the Chicken. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2021</b> , 106, e1897-e1899	5.6	3
14	Combination therapy with pioglitazone/exenatide improves beta-cell function and produces superior glycaemic control compared with basal/bolus insulin in poorly controlled type 2 diabetes: A 3-year follow-up of the Qatar study. <i>Diabetes, Obesity and Metabolism</i> , <b>2020</b> , 22, 2287-2294	6.7	2
13	Improved Beta Cell Glucose Sensitivity Plays Predominant Role in the Decrease in HbA1c with Cana and Lira in T2DM. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2020</b> , 105,	5.6	2

12	Exenatide modulates visual cortex responses. <i>Diabetes/Metabolism Research and Reviews</i> , <b>2019</b> , 35, e31675	1
11	Combination therapy in type 2 diabetes mellitus <b>2015</b> , 686-708	1
10	Clinical Parameters, Fuel Oxidation, and Glucose Kinetics in Patients With Type 2 Diabetes Treated With Dapagliflozin Plus Saxagliptin. <i>Diabetes Care</i> , <b>2020</b> , 43, 2519-2527	14.6 1
9	Insulin secretion is a strong predictor for need of insulin therapy in patients with new-onset diabetes and HbA1c of more than 10%: A post hoc analysis of the EDICT study. <i>Diabetes, Obesity and Metabolism</i> , <b>2021</b> , 23, 1631-1639	6.7 1
8	Pioglitazone prevents the increase in plasma ketone concentration associated with dapagliflozin in insulin-treated T2DM patients: Results from the Qatar Study. <i>Diabetes, Obesity and Metabolism</i> , <b>2019</b> , 21, 705-709	6.7 1
7	Dapagliflozin Impairs the Suppression of Endogenous Glucose Production in Type 2 Diabetes Following Oral Glucose.. <i>Diabetes Care</i> , <b>2022</b> ,	14.6 1
6	Sodium-Glucose Cotransporter 2 Inhibitors and the Kidney. <i>Diabetes Spectrum</i> , <b>2021</b> , 34, 225-234	1.9 0
5	Insulin Secretion Predicts the Response to Antidiabetic Therapy in Patients With New-onset Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2021</b> , 106, 3497-3504	5.6 0
4	Comprehensive analysis of circulating miRNA expression profiles in insulin resistance and type 2 diabetes in Qatari population <b>2022</b> , 15, 191-202	
3	Preface: Cardiorenal Considerations for Type 2 Diabetes-Time to Exit the Dark Ages. <i>Diabetes Spectrum</i> , <b>2021</b> , 34, 214-215	1.9
2	Personalized approach for type 2 diabetes pharmacotherapy: where are we and where do we need to be?. <i>Expert Opinion on Pharmacotherapy</i> , <b>2021</b> , 22, 2113-2125	4
1	Comparison of the effects of human recombinant insulin-like growth factor I and insulin on plasma amino acid concentrations and leucine kinetics in humans. <i>Diabetologia</i> , <b>1995</b> , 38, 732-738	10.3